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Background
Cervical human papillomavirus (HPV) infections and
abnormal cervical cytology are more prevalent and per-
sistent in HIV-infected compared with uninfected women.
Less is known about anal HPV infections and abnormal
anal cytology in women and whether findings in the cer-
vix correlate with findings in the anus. The correlation
between cytology and histology in the anal area has been
even less studied. Here we evaluate the prevalence of anal
and cervical cytologic abnormalities and evaluate if the
abnormal cytology is associated with abnormal histology
as evaluated by biopsies.
Methods
This is a cross sectional study of HIV-infected patients
receiving care at the Miriam Hospital, Providence, Rhode
Island. All women that were due for the annual cervical
Pap smear were offered to participate in the study. Each
participant had cervical and anal swabs for cytopathologic
examination (Pap tests) and cervical and anal cytobrush
and swab obtained for HPV typing. Any abnormal cytol-
ogy was followed up with a colposcopy and anoscopy
respectively and biopsies obtained.
Results
Cervical and anal cytology results were available for 80
women. Mean age was 43 years (range 24–60), and race
was 50 percent white, 34 percent African American, 14
percent Hispanic, 10 percent other. The median CD4
count was 564 cells/mm3 (range 44 to 1470 cells/mm3).
Fourteen women (18%) were antiretroviral naïve, 64
women (80%) were taking antiretroviral therapy, and two
had an unknown medication history. The mean HIV viral
load was 18,318 copies/mL, 56 percent of the women had
an undetectable HIV viral load. The prevalence of an
abnormal cytology (atypical squamous cells of undeter-
mined significance [ASCUS], low- or high-grade squa-
mous intraepithelial lesions [SIL]) in anus or cervix was
40 percent (32 out of 80 women); 22 percent in the anus,
and 26 percent in the cervix (not statistically significant).
Eight out of 32 women (25%) had an abnormal cytology
at both anatomical areas, 10 of 32 (31%) women had an
abnormal anal cytology only, and 14 of 32 (44%) women
had an abnormal cervical cytology only. Up to date, 5 out
of 18 women with an abnormal anal cytology have under-
gone anoscopy with biopsy results that were all normal.
Nine women out of the 22 women that had an abnormal
cervical Pap smear have had a colposcopy with biopsy and
only one cervical intraepithelial neoplasia II.
Conclusion
Preliminary results in this cohort of HIV-infected women
with a high mean CD4 cell count shows that there is a
high prevalence of abnormal cytology and it is similar in
both cervix and anus. The majority of women had abnor-
mal cytology in either anus or cervix but not both. A lim-
ited number of women have undergone histology
sampling, and all but one had normal results. Additional
biopsies have been scheduled and HPV typing is being
analyzed.
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